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Abstract 
This report highlights the drivers, challenges and enablers of the hybrid modelling applications in 
biopharmaceutical industry. It is a summary of an expert panel discussion of European academics 
and industrialists with relevant scientific and engineering backgrounds. Hybrid modelling is 
viewed in its broader sense, namely as the integration of different knowledge sources in form of 
parametric and nonparametric models into a hybrid semi-parametric model, for instance the 
integration of fundamental and data-driven models. A brief description of the current state-of-
the-art and industrial uptake of the methodology is provided. The report concludes with a number 
of recommendations to facilitate further developments and a wider industrial application of this 
modelling approach. These recommendations are limited to further exploiting the benefits of this 
methodology within PAT applications in biopharmaceutical industry. 
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1. Background and purpose of the panel report 
Traditionally, bioprocess models were developed by translating the fundamental knowledge 
about the process into mathematical equations, subsequently testing and improving the model 
hypotheses in comparison to experiments. A model formulated this way can be classified as a 
parametric model and its development is typically laborious. In recent years, data-driven 
approaches have increasingly been applied for bioprocess modelling, as those approaches require 
limited knowledge about the process and their development is systematic and easy. Those data-
driven approaches can be classified as nonparametric models. This does not imply that they do 
not have parameters, only that the structure of those models is determined from data. The 
combination of parametric and nonparametric models results in hybrid semi-parametric models 
[1, 2], although typically referred to as hybrid models. Hybrid modelling in a broader sense can 
be viewed as a way of integrating and structuring process knowledge and information gained 
from various sources. A typical example is the modelling of kinetic rate expressions using data-
driven techniques (frequently using neural networks), which are embedded in a dynamic material 
balance parametric framework [3, 4]. Since hybrid models can exploit a broader knowledge base, 
they offer a cost-effective methodology for the solution of complex problems. 
 
This expert panel report focuses on highlighting the progress in applying hybrid modelling in 
biopharmaceutical industries, briefly compared to other industrial sectors, and the challenges to 
be addressed for effective application within the Quality by Design (QbD) and PAT frameworks 
outlined in guidance documents [5-7]. The advances in the application of hybrid modelling in 
other subject areas and industrial sectors are not addressed in detail in this report. 
Applications of hybrid models to bioprocesses focused so far on upstream processes, namely on 
monitoring [1, 3, 4, 8-11], control [1, 4, 11-12] and optimisation [1, 3, 4, 11, 13-15] of fermentation 
processes. In comparison to strictly nonparametric approaches, hybrid models usually provided a 
significantly increased performance, subsequently improving process operation [1]. Despite the 
advantages, hybrid models have received relatively little attention in biopharma as compared to 
classical pharmaceutical processes [16] but especially as compared to the chemical [17] and 
petrochemical sector [18]. In these sectors more advanced hybrid modelling approaches have 
been developed and their application to control [19], optimisation [20-21] and also scale-up [22] 
penetrated to the industrial sector. However, the introduction of the PAT initiative in 2004 
provides the opportunity for advanced modelling and process control to contribute to improved 
bioprocess performance [5]. With squeezing profit margins and the patent life of a new chemical 
entity or formulation not producing as much return on investment as previously enjoyed [23], the 
impact of hybrid models would be more profound. 
2. Business drivers and regulatory pressures  
Process understanding, continuous quality improvement and risk analysis are the cornerstones 
of a robust scientific approach for modern drug development and manufacturing, and of the 
requirements of the ICH and FDA guidelines [5, 7, 24-25]. These regulatory and quality concerns 
combined with the commercial imperative are significant drivers for developments in the 
biopharmaceutical industry. 
The basis of QbD is to understand the sources of variability in the process and product and to 
understand the linkages so that variability can be controlled [24-25]. In particular, the 
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identification and assessment of Critical Quality Attributes (CQAs) and Critical Process Parameters 
(CPPs) requires an appropriate scientific model of the process. Such a model maintains required 
process knowledge through the lifecycle of the drug [24]. 
The diverse nature of biopharmaceutical products translates into diverse business drivers, but 
common themes exist across the sector. New candidates can be identified by discovery R&D, in-
licensed or acquired from a third party. Also, new therapeutic indications for an existing candidate 
can be identified. During development, the emphasis is on achieving fast to First time in human 
(FTIH) and Proof of Concept (POC) clinical studies, to be ‘First-in-Class’, i.e. it is common for 
several companies to be simultaneously pursuing promising new targets [26], therefore being first 
in a particular new class of drugs can distinguish between commercial success and failure. Short 
timelines leave little room for establishing detailed models of the process. Complications are 
added by scale-up and process transfer between facilities. Mitigating the risk of clinical failure 
often means realizing FTIH clinical studies under timeline and resource constraints.  
Later entrants to a drug class market (‘biosimilars’) may aim to be ‘Best-in-Class’ (‘biosuperiors’), 
providing further competition [26]. Biosimilars as a whole are expected to retain a considerable 
price, estimated at 65% to 85% of the original [27]. The biosimilars market is estimated to reach 
$7-8 billion by 2020, exciting industry interest and concern [28]. A number of key industry players 
have, or have announced their intention, to enter biosimilar manufacturing (e.g. 
http://www.gabionline.net/Biosimilars/News/Samsung-makes-biosimilars-deal-with-Biogen-
Idec ) [29].  
Biopharmaceuticals are entering a competitive era, in which a lack of process optimisation means 
that the expiration of a patent will lead to diminishing profits. The opportunity is for biosimilar 
manufacturers with process modelling and process understanding to produce a variety of 
biosimilars, and be less vulnerable to fluctuations in their pipeline.  
These drivers demand modelling methods that enable effective process optimisation, monitoring 
and control, and minimise sub-optimal product selection or process implementation. Ultimately, 
this is to the benefit of patient safety. 
3. Current applications and future potential 
3.1 Process development 
Early biopharmaceutical process development often starts with minimal or no experimental data, 
but rarely with a complete absence of previous knowledge. Traditional approaches to process 
development have often relied on combining this knowledge with established models that can be 
limited in scope. 
In comparison, statistical methods of experimental analysis, such as those commonly applied in 
association with Design of Experiments (DoE) principles, e.g. MVDA, disregard any previous 
knowledge and generate a model based purely on fitting defined relationships to the 
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experimental data. For establishing statistical significance this demands a non-trivial 
experimental data set, which may not be available at the beginning of early process development, 
and the generation of which can represent a considerable resource investment. 
Hybrid semi-parametric modelling allows incorporating the existing body of knowledge into a 
structured framework that adapts the projected relationships according to experimental data as 
it is collated. As such it promises an economic method for building practical and flexible models.  
Whilst literature reports the optimisation of product titres in the upstream process [1], 
downstream unit operations are often more likely to be on the critical path for process 
development. Reports of applications of hybrid modelling to address product quality issues are 
currently limited and its suitability to downstream process unit operations such as 
chromatography optimisation, product purity, oligomerization or aggregation, has yet to be 
demonstrated fully [30].  
The complexity of integrating multiple operations in process development is another significant 
challenge that may be suited to the flexible framework provided by hybrid semi-parametric 
models. 
High throughput systems are being implemented across process development disciplines to 
better address the challenges of rapid product/ process optimisation. These systems are being 
increasingly integrated with statistical DoE and MVDA packages to manage the large data-sets 
generated. They also constitute suitable platforms for the incorporation of hybrid modelling 
software tools exploiting the available process knowledge (hybrid model) to iteratively design a 
series of experiments aiming either at the exploration of the space or the exploration of the 
optimal process conditions [1, 14-15]. These model-based experimental design approaches 
generally allow either to reach the optimal process conditions faster than with standard DoEs or 
to improve a particular model for a specific operation space. 
3.2 Manufacturing operations  
The objective during manufacturing operations is to delimit process variations as much as 
possible. In the QbD and PAT context, the intention is to reduce variability by identifying and, 
where possible, eliminating the sources of variability and ultimately to counteract the remaining 
variations by using advanced process control. Thus models that enable analysing the process, 
tracing back variability and applying advanced process control are required. The development of 
such models is challenging since the biopharmaceutical manufacturing processes are typically 
highly complex and not well understood. Different approaches can be applied to model the 
process, namely fundamental models, data-driven models and hybrid models with advantages 
and limitations of each approach shown in Table 1. The application of hybrid models is particularly 
efficient when the model can link different sources of knowledge, since the requirements on the 
data (both quantity and quality) can decrease and the models inter- and extrapolation properties 
may improve (Figure 1 and Table 2). This is especially important for process optimisation since 
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the model should accurately predict offline how the process will perform for conditions that have 
not yet been tested experimentally, which requires a rather global process understanding, see 
Figure 1c. Global process understanding, which ranges beyond the process space characterized 
by design of experiments, requires the model to have good extrapolation properties, a property 
that is typically associated with more fundamental knowledge (Figure 1b). Hybrid models have 
proven effective for the process optimisation of a range of manufacturing scales and for the 
manufacturing of various products [1, 3, 4, 11, 13-15], e.g. Preusting et al. [31] developed a hybrid 
model to optimize the operational procedure of a large-scale penicillin production process.  
For online applications, such as monitoring or control, slightly different model properties are 
required. For monitoring and supervision the model should typically represent the fermentation 
state/cultivation state based on the online measurements. During production, the process will 
normally run within the operation space, which is well characterized by DoE and the local process 
understanding is sufficient (Figure 1c). In this space data-driven approaches can perform well 
(Figure 1b). However, while it is feasible to correlate e.g. the biomass concentration to pH, 
dissolved oxygen concentration or/and to dielectric probe signal, the correlation to product 
concentrations or even product quality is not straightforward, one reason being the relatively low 
product titres. Integrating fundamental knowledge with data-driven techniques may reduce 
these limitations. Several successful applications of hybrid models for process monitoring have 
been reported [1, 3, 4, 8-11]. Process control requires robust models that can describe the process 
dynamics and have appropriate extrapolation properties, particularly for frequency 
extrapolation. This becomes even more critical when moving towards online predictive or optimal 
control since the process has to be understood beyond the region in which the process was 
validated in order to describe its behaviour at the limits (Figure 1c).  As hybrid models are typically 
inherently dynamic and as they can predict the process state accurately even for novel process 
conditions [1], they offer a very suitable method for accurate process control beyond prior tested 
conditions [12]. Moreover they are more transparent than e.g. data-driven approaches, allowing 
scrutinizing and correcting the control action, where necessary [12]. Very few applications for 
process supervision and control have so far been reported [1, 4, 11], but e.g. Dors et al. [32] 
showed that hybrid models can supervise a production-scale mammalian cell culture process 
operated in a repeated fed-batch mode and predict the best times for harvesting and the restart 
of the next fed-batch phase.  
4. Future challenges  
4.1 New theories and software  
The hybrid semi-parametric modelling framework is at present not fully established and several 
open questions exist [1]. With respect to PAT-applications in (bio)pharmaceutical industry, major 
concerns are i) model validation; ii) compliance with FDA software regulations [7, 33] for software 
use in process monitoring or closed-loop control. With respect to the above outlined benefits, 
hybrid modelling tools can be introduced step-wise, starting from off-line utilization for process 
analysis, optimisation or scale-up towards their on-line use for monitoring, supervision or closed-
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loop control, thus supporting the knowledge transfer from process development to 
manufacturing.  
From an end-user perspective, hybrid modelling tools must be user-friendly and flexible with 
respect to the integration of different knowledge sources [34] and also to data acquisition and 
pre-processing ( http://ht.ly/hpoX5 ), see Figure 2. Data treatment can be time-consuming, 
subject to errors and it can significantly impact on the model performance. The tools should be 
integrated into existing industrial Distributed Control Systems (DCS) and PAT data management 
platforms, extensively documented and the interfaces standardized [35]. To our knowledge, there 
are no hybrid modelling tools available yet that meet all mentioned requirements and could be 
applied in industry. 
4.2 Model development process  
The development process of hybrid models to date mostly relies on the modeller’s experience 
and no systematic and integrated model development approach has so far been proposed. 
Central to the development of a hybrid model is its subsequent use. For example, a model for 
control will aim to capture the transient behaviour (frequency extra-/interpolation) more so than 
a model for optimisation. In line with this model objective, the available knowledge is assessed, 
deciding how and what to integrate (Figure 2). For serial hybrid models (Figure 3) it is important 
considering that the parametric model (the a priori incorporated fundamental knowledge) 
possesses an inductive bias for the subsequent identification of the nonparametric model [1, 3]. 
Therefore, an iterative model building approach should be employed, starting with the most 
generic model (containing limited fundamental knowledge) and subsequently incorporating more 
fundamental knowledge. For each of the structures the identification of the nonparametric model 
is necessary, which may be challenging for complex models [1]. Model performance criteria, such 
as BIC, AIC or MSE [36], allow the performance of different models to be compared against the 
experimental data. Assessing the nonparametric model outputs over time and over the inputs (or 
at least a subset of inputs) and analysing the model validity space can provide insights into further 
model improvements. The validity space is assumed to be mostly delimited by the input values of 
the nonparametric model [1, 37], since the data-driven models do not extrapolate well (Figure 
1b). The form of this space can be manipulated through the choice of input variables and their 
value ranges. The value ranges can be systematically varied through the design of experiments 
and subsequently this design can be used for the segregation of the experimental data into 
training, validation and test sets.  
Once a model is accepted (Figure 2), the modelling report should detail the model development 
history and testing. While a model can subsequently be improved by augmenting the existing data 
set with new data, strict version control should be applied when making any changes. Regular 
evaluation of model performance should be carried out and documented. 
A model impact risk assessment should be carried out prior to any equipment changes such as 
sensor recalibration, equipment servicing or modification. Changes to process feed stocks and 
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raw materials can also have an impact on model performance and a model may require controlled 
updates. 
5 Recommendations 
The application of hybrid models in (bio)pharmaceutical industry can be significantly enhanced 
by the following initiatives: 
1. Increased number of industrial case studies describing the optimisation of business 
relevant process variables. For instance, the incorporation of knowledge about 
glycosylation mechanism into the hybrid process model could potentially enable the 
optimisation of the process with respect to desired glycosylation patterns, and as such 
represent an important business case. Similarly, the optimization of the complete 
production strategy with respect to the process bottleneck while ensuring product quality 
represents an important business driver. The more accurately the model can describe the 
bottleneck unit, the greater the potential impact when optimising the overall process. As 
outlined in several places in this article, hybrid models have been shown to offer improved 
prediction performance compared to other modelling methods. 
2. Case studies reporting the use of hybrid modelling approaches in on-line process control of 
product related critical process parameters concentrating on processes relevant to the 
industry. These would ideally include industry relevant studies that report on (predictive) 
on-line control of product quality and the influence on critical process parameters upon 
CQAs.  
3. Knowledge transfer from research to industry, communicating it in different forms to the 
various hierarchical levels, in order to sensitise and increase awareness for hybrid 
modelling approaches and their benefits. This comprises the sketching of scenarios under 
which hybrid modelling approaches could produce benefits for more management 
oriented personal and education for staff that will have to understand how to implement 
the approaches to generate the benefits.  
4. User-friendly software hybrid model solutions, fully integratable within existing systems 
and easily validatable. 
5. Introduction of a systematic and integrated approach for hybrid model development. 
6. Development of a procedure that can determine the limitations of hybrid models with 
respect to changes in certain variables, thus delimiting the process operation and design 
region for which the model can faithfully describe the process. This procedure will help 
validating the process when its performance critically depends on monitoring and control 
action that in turn was calculated using hybrid models. 
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Table 1. Conventional process model features vs. hybrid semi-parametric models. 
Parametric / Fundamental 
 Based on first-principles, mechanistic or empirical knowledge 
about the system 
 Parameters have a physical meaning 
 Model structure is fixed through system knowledge  
 Model development is laborious  
 Good extrapolation properties  
 Examples: 
- Material / Energy / Momentum laws 
- Thermodynamic laws 
- Reaction kinetics 
 
Nonparametric/ Data-driven 
 Based on process data provided by the system 
 Parameters have no physical meaning  
 Model structure is identified from data  
 Models are quickly applicable 
 Descriptive quality within experimentally explored region 
only 
 Examples: 
- Artificial Neural Networks 
- Partial Least Square Regression 
- Splines, kernels, wavelets 
Hybrid semi-parametric 
SYNERGY BENEFITS 
 Exploitation of advantages/ Reduction of disadvantages of particular modelling techniques 
 Improved modelling / prediction quality 
 More efficient model development 
 Better benefit / cost ratio when solving complex problems 
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Table 2: Application-specific requirements on modelling methods and respective (dis-)advantages of hybrid models 
Application Requirements Advantages/ Disadvantage of hybrid models  
Process Development  Support maximising product yield 
 Integration of various knowledge sources should be feasible 
 Impact of several factors must be studied 
 Extrapolation properties 
 Potentially fewer experiments required than for the 
development of pure data-based models 
 More user-intensive than data driven approaches 
 Allows to study impact of certain variables without the 
execution of experiments, e.g. for the initial biomass 
concentration 
 May provide good extra- and interpolation properties  
 May require DoE for identification of the nonparametric 
model 
Process Scale-up  Support scale-up of the process to manufacturing scale 
 Extrapolation properties 
 Account for  scale dependent phenomena, e.g.: the influence of 
transport phenomena on gross kinetic expressions at production 
scale 
 Experimental studies (partial DoEs) required to study the 
scale specific phenomena 
 Influence of transport phenomena on gross kinetic 
expressions at production scale can be accounted for, see 
e.g. [39] 
 May provide good extra- and interpolation properties 
Process Optimisation  Allow to increase process robustness 
 Extrapolation and Interpolation properties 
 Impact of several factors must be incorporated 
 Several sources of knowledge should be integrated  
 Potentially fewer experiments required 
 Allows to study impact of variables without executing 
complete DoE 
 Easier to incorporate the influence of factors 
 Convergence to the optimum is not ensured 
Process Validation  Demonstrate that the process is understood within the process 
operation space 
 Impact of factors on process and product quality (also changes 
with time) must be understood 
 Interpolation properties 
 Studies on certain factors can be more easily integrated than 
for fundamental models 
 Easier to capture the dynamic effects with hybrid modelling 
approaches than with data driven ones 
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Process Monitoring  Enable reliable tracking of the process performance 
 Support decision making 
 Interpolation (and extrapolation) 
 Development of models takes slightly longer with increasing 
number of inputs 
 Model predictions may be bound [1], therefore e.g. no 
negative substrate concentrations predicted  
 More data can be used for calibration than for data-driven 
models [9] 
 Process prediction and online optimisation or decision 
support feasible with dynamic models 
Process Control  Ensure that the process stays within the approved operation 
space 
 Multivariate control to act on the remaining process variability 
 Cell dependent time restrictions for control action 
 Control action should be analysable 
 Easy to capture multivariate effects [12] 
 Multivariate control becomes possible (e.g. MPC, optimal 
control)  
 Better analysability of control action than for data-driven 
models [12] 
 May be difficult to assess stability, robustness 
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Figure Legends 
 
Figure 1: Schematic diagrams for A) The comparison of modelling methods in relation to the available fundamental knowledge/ requirements 
on data; B) The comparison of modelling methods in relation to the process understanding and the expenses for model development; and C) 
The requirements of process operation and design approaches on process understanding for a certain level of performance. 
 
Figure 2: Process flows for data acquisition prior to modelling and for model lifecycle. Additional steps in the modelling analysis cycle must be 
considered for creating hybrid models in comparison to creating multivariate models [38]. 
 
Figure 3. Schematic representation of hybrid model structures. A) Serial Structure; B) Serial structure with feed-back of state-variables; C) 
Parallel structure.  
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